Dhavalkumar Dhirajlal Patel - 26 Aug 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Reporting relationship: EVP, Chief Scientific Officer
Issuer ticker: SANA
Reported as of: 26 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Aug 2026, 16:21:33 UTC
Prior SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel

Key filing fact

Dhavalkumar Dhirajlal Patel filed Form 4 for Sana Biotechnology, Inc. (SANA) on 27 Aug 2026.

Key facts

This page summarizes Dhavalkumar Dhirajlal Patel's Form 4 filing for Sana Biotechnology, Inc. (SANA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Aug 2026, 16:21.

Change

Previous filing in this sequence was filed on 27 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002115339 Primary reporting owner

PATEL DHAVALKUMAR DHIRAJLAL

Relationship: EVP, Chief Scientific Officer
Address: C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SANA transaction

Common Stock

Options Exercise

Transaction value
Shares: +125,000
Change %: +126%
Price: $0.000000^*
Shares after: 224,510
Date: 26 Aug 2026
Ownership: Direct

SANA transaction

Common Stock

Tax liability

Transaction value
Shares: -41,158
Change %: -18%
Price: $4.11^*
Shares after: 183,352
Date: 27 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SANA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -125,000
Change %: -33%
Price: $0.000000^*
Shares after: 250,000
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.

Footnote F2

The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.